Novavax Company Profile (NASDAQ:NVAX)

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Tuesday, August, 8th. The company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.16). The company earned $6.70 million during the quarter, compared to the consensus estimate of $6.15 million. Novavax had a negative net margin of 1,006.00% and a negative return on equity of 787.38%. The firm's revenue for the quarter was up 168.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.29) earnings per share. View Novavax's Earnings History.

9 brokers have issued 1 year price targets for Novavax's stock. Their predictions range from $1.17 to $25.00. On average, they expect Novavax's stock price to reach $5.31 in the next twelve months. View Analyst Ratings for Novavax.

Here are some recent quotes from research analysts about Novavax stock:

• 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (8/19/2017)
• 2. Cantor Fitzgerald analysts commented, "Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock." (7/21/2017)
• 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)

Novavax saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 55,513,144 shares, an increase of 1.6% from the July 14th total of 54,638,918 shares. Based on an average daily trading volume, of 16,654,968 shares, the days-to-cover ratio is currently 3.3 days. Currently, 19.9% of the shares of the stock are short sold.

Some companies that are related to Novavax include ImmunoGen (IMGN), ANI Pharmaceuticals (ANIP), KALA PHARMCTLS (KALA), Inovio Pharmaceuticals (INO), WAVE Life Sciences (WVE), AC Immune SA (ACIU), Cara Therapeutics (CARA), PDL BioPharma (PDLI), Celyad SA (CYAD), Agenus (AGEN), Concert Pharmaceuticals (CNCE), Adamas Pharmaceuticals (ADMS), Abeona Therapeutics (ABEO), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX), Codexis (CDXS), Idera Pharmaceuticals (IDRA) and Corvus Pharmaceuticals (CRVS).

Novavax's management team includes the folowing people:

• James Francis Young Ph.D., Independent Chairman of the Board
• Stanley C. Erck, President, Chief Executive Officer, Director
• Barclay A. Phillips, Chief Financial Officer, Senior Vice President, Treasurer
• Gregory M. Glenn M.D., President, Research and Development
• John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary
• John J. Trizzino, Senior Vice President - Commercial Operations
• James F. Cummings, Vice President - Clinical Development and Translational Medicine
• Rajiv I. Modi Ph.D., Director
• Gail Koziara Boudreaux, Independent Director
• Richard H. Douglas Ph.D., Independent Director

Novavax's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.16%), FMR LLC (5.11%), BB Biotech AG (2.95%), State Street Corp (1.82%), JPMorgan Chase & Co. (1.84%) and Northern Trust Corp (1.19%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Novavax's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., FMR LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, California State Teachers Retirement System, ProShare Advisors LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Novavax.

Novavax's stock was bought by a variety of institutional investors in the last quarter, including Chicago Equity Partners LLC, JPMorgan Chase & Co., Nationwide Fund Advisors, GSA Capital Partners LLP, Canada Pension Plan Investment Board, Schwab Charles Investment Management Inc., Federated Investors Inc. PA and State of Wisconsin Investment Board. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Novavax stock can currently be purchased for approximately $1.00.